Re: Lin I, Melsheimer R, Bhak RH, et al. Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab. Curr Med Res Opin. 2022;38(4):613

Re: Lin I, Melsheimer R, Bhak RH, et al. Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab. Curr Med Res Opin. 2022;38(4):613–627

Published:2022-08-25 Issue:12 Volume:38 Page:2241-2242
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Pham Codey¹,Tomcsanyi Kelly M.²³,Waljee Akbar K.⁴⁵⁶,Hou Jason K.⁷

Affiliation:

1. Department of Medicine, Baylor College of Medicine, Houston, TX, USA

2. VA Pittsburgh Healthcare System, VA Center for Medication Safety (VA MedSAFE), Pittsburgh, PA, USA

3. VA Pittsburgh Healthcare System, Center for Health Equity Research and Promotion (CHERP), Pittsburgh, PA, USA

4. Health Services Research and Development Center of Clinical Management Research, VA Ann Arbor, Ann Arbor, MI, USA

5. Michigan Integrated Center for Health Analytics and Medical Prediction (MiCHAMP), Ann Arbor, MI, USA

6. Department of Internal Medicine, Division of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, MI, USA

7. Department of Medicine, Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, TX, USA

Funder

VA Health Services Research and Development

VA HSR&D Center for Innovations in Quality, Effectiveness and Safety

Redhill Biosciences, Janssen, Abbvie, Celgene, Genentech, Eli-Lily, Lycera, and Pfizer Inc

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2022.2113694

Reference3 articles.

1. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

2. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

3. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Author’s Response to Letter to the Editor - Re: Lin I, Melsheimer R, Bhak RH, et al. Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab. Curr Med Res Opin. 2022;38(4):613–627;Current Medical Research and Opinion;2022-11-07